EFM
RCUS icon

E Fund Management’s Arcus Biosciences RCUS Stock Holding History

E Fund Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$312K Sell
10,113
-4,360
-30% -$108K 0.01% 373
2026
Q1 		$313K Buy
+14,473
New +$313K 0.01% 387
2025
Q2 		$89.4K Buy
10,987
+489
+5% +$4.18K ﹤0.01% 378
2025
Q1 		$82.4K Buy
+10,498
New +$122K ﹤0.01% 388
2024
Q2 		– Sell
-16,052
Closed -$303K – 365
2024
Q1 		$303K Buy
16,052
+2,551
+19% +$44.1K 0.02% 274
2023
Q4 		$258K Sell
13,501
-1,537
-10% -$24.6K 0.02% 252
2023
Q3 		$270K Sell
15,038
-1,098
-7% -$22.1K 0.02% 220
2023
Q2 		$328K Sell
16,136
-7,199
-31% -$137K 0.03% 207
2023
Q1 		$426K Buy
23,335
+13,121
+128% +$251K 0.03% 146
2022
Q4 		$211K Sell
10,214
-5,506
-35% -$152K 0.02% 295
2022
Q3 		$411K Sell
15,720
-2,055
-12% -$54.3K 0.04% 176
2022
Q2 		$450K Buy
17,775
+9,670
+119% +$237K 0.04% 164
2022
Q1 		$256K Buy
+8,105
New +$272K 0.01% 254

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

E Fund Management's RCUS Position: Q2 2026 in Review

E Fund Management reduced its Arcus Biosciences (RCUS) stake by 30% in Q2 2026, selling an estimated $108K and leaving 10,113 shares worth $312K. The position accounts for 0.01% of the portfolio, ranked #373.

E Fund Management first reported a position in RCUS in Q1 2022 and has held it in 13 quarters since. The position peaked at $450K in Q2 2022. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • E Fund Management held 10,113 shares of Arcus Biosciences worth $312K as of Q2 2026.
  • E Fund Management sold 4,360 Arcus Biosciences shares in Q2 2026, an estimated $108K.
  • Arcus Biosciences made up 0.01% of E Fund Management's portfolio in Q2 2026, its #373 holding.
  • E Fund Management first reported a position in Arcus Biosciences in Q1 2022 and has held it in 13 quarters since.
  • E Fund Management's Arcus Biosciences position peaked at $450K in Q2 2022.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.